C2i Genomics is a biotech startup that has developed a groundbreaking blood test for detecting and quantifying residual cancer cells. This innovative technology addresses a significant gap in the current cancer treatment landscape, where tiny amounts of residual cancer cells may remain undetectable after surgery. C2i's ultra-sensitive test can identify these cells, enabling more precise personalized treatment and monitoring, reducing overall treatment costs, and accelerating drug development.

The company's technology is accessible globally, expanding the reach of precision cancer monitoring. This has multiple applications throughout a patient's treatment timeline, providing valuable data to inform treatment decisions and monitor progress.

C2i Genomics also offers its Minimal Residual Disease (MRD) monitoring and cancer Intelligence Platform to pharmaceutical and research partners. This platform can be used in clinical trials and research, providing accurate enrollment and highly sensitive and specific surrogate endpoints. This means that the platform can help speed up clinical trials by providing more precise and reliable data.

The company's executive team has a wealth of experience from military intelligence and leading biotech companies, including the New York Genome Center, Bristol-Myers Squibb, GlaxoSmithKline, Tempus, Foundation Medicine, and Amwell.

C2i Genomics operates in the biotech and healthcare market, serving clients such as healthcare providers, researchers, and pharmaceutical companies. Its business model revolves around providing its proprietary cancer detection and monitoring technology and services to these clients, generating revenue through service fees and partnerships.

Keywords: Cancer Detection, Biotech Startup, Personalized Medicine, Residual Cancer Cells, Global Accessibility, Clinical Trials, Pharmaceutical Research, Minimal Residual Disease Monitoring, Cancer Intelligence Platform, Precision Cancer Monitoring.